Peptides for me FAQ

Continue the protocol through at least 12 weeks before reassessing. Thymic reconstitution requires 8–12 weeks for CD4+ T-cell maturation from naive precursors to functional effector cells. Thymopoiesis isn't an acute process. Clinical trials showing Thymalin efficacy measured outcomes at 12-week endpoints, not 4-week. The exception is MK-677: if IGF-1 levels don't increase by week 4 (verifiable through serum testing), either absorption is impaired or the ghrelin receptor pathway isn't the limiting factor in your specific case.

Start with immune reconstitution first. Thymalin's restoration of regulatory T-cells (Tregs) reduces systemic inflammation that drives secondary neuroinflammation. A 2021 study in autoimmune encephalitis patients showed that Treg restoration via thymic peptides reduced CNS inflammation markers by 38%. Without direct CNS-targeted therapy. Complete one full Thymalin cycle (3 months, 3 pulse rounds) before adding Cerebrolysin or P21. Stacking immune and neurotrophic peptides simultaneously makes it impossible to isolate which mechanism drove improvement or adverse effects.

This reflects immune reconstitution inflammatory syndrome (IRIS). A transient worsening of symptoms as the immune system reactivates and clears latent viral reservoirs or damaged cells. It occurs in 15–25% of patients starting thymic peptides and typically resolves within 7–10 days. Reduce the next Thymalin dose by 50% (5mg instead of 10mg) and extend the interval between injections to every other day instead of daily. Once symptoms stabilise, resume standard dosing.

No. Thymalin and immunosuppressants work through opposing mechanisms. Thymalin activates T-cell proliferation; drugs like methotrexate, azathioprine, or corticosteroids suppress it. The interaction isn't just ineffective. It's counterproductive. If you're tapering off immunosuppressants under medical supervision, wait until you've been off the medication for at least 4 weeks (one full T-cell turnover cycle) before starting Thymalin. This washout period ensures the thymus isn't receiving simultaneous activation and suppression signals.

Target mitochondrial ATP production through growth hormone pathways. MK-677 or CJC-1295/Ipamorelin combinations. PEM reflects the inability of mitochondria to meet ATP demand during and after exertion, forcing anaerobic metabolism that produces lactate accumulation and triggers symptom crashes 12–48 hours later. Growth hormone stimulates PGC-1alpha, the transcription factor that upregulates mitochondrial DNA replication and oxidative phosphorylation enzyme expression. Expect 8–12 weeks before mitochondrial biogenesis translates to measurable increases in exercise tolerance. Track with daily step counts, heart rate variability, or lactate threshold testing if available.

Start with immune-modulating peptides like Thymalin before adding neurotrophic or mitochondrial compounds. Flow cytometry showing CD4+CD25+FoxP3+ Treg percentages below 5% (normal range 5–10%) combined with elevated IL-6 or IL-17 indicates the immune arm of ME/CFS pathology is dominant. Addressing that first often improves downstream symptoms including brain fog and PEM, because chronic inflammation itself impairs mitochondrial function. Dose 5–10mg subcutaneously 2–3 times weekly for 12 weeks, with repeat immune panels at week 6 and week 12 to confirm Treg expansion and cytokine reduction.

Prioritize neurotrophic peptides. Cerebrolysin or Dihexa. Over growth hormone secretagogues. Baseline cognitive testing (Trail Making Test Part B, Stroop interference score, verbal fluency) establishes quantifiable deficits that correlate with BDNF-dependent synaptic plasticity. Cerebrolysin requires IV administration but has the strongest human evidence base; Dihexa is subcutaneous and experimental but shows higher synaptogenic potency in preclinical models. Pair with quantitative EEG or functional MRI at baseline and endpoint to track prefrontal cortex activation patterns. Subjective reports of 'mental clarity' vary widely, but objective neuroimaging provides reproducible data.